|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ZNF770 |
Gene summary for ZNF770 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ZNF770 | Gene ID | 54989 |
| Gene name | zinc finger protein 770 | |
| Gene Alias | PRO1914 | |
| Cytomap | 15q14 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q6IQ21 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 54989 | ZNF770 | PTC05 | Human | Thyroid | PTC | 2.87e-25 | 1.03e+00 | 0.2065 |
| 54989 | ZNF770 | PTC06 | Human | Thyroid | PTC | 4.36e-27 | 1.04e+00 | 0.2057 |
| 54989 | ZNF770 | PTC07 | Human | Thyroid | PTC | 5.90e-48 | 7.82e-01 | 0.2044 |
| 54989 | ZNF770 | ATC09 | Human | Thyroid | ATC | 1.67e-04 | 5.79e-02 | 0.2871 |
| 54989 | ZNF770 | ATC12 | Human | Thyroid | ATC | 1.75e-10 | 1.11e-01 | 0.34 |
| 54989 | ZNF770 | ATC13 | Human | Thyroid | ATC | 1.39e-11 | 2.14e-01 | 0.34 |
| 54989 | ZNF770 | ATC1 | Human | Thyroid | ATC | 1.90e-03 | 6.42e-02 | 0.2878 |
| 54989 | ZNF770 | ATC2 | Human | Thyroid | ATC | 5.59e-07 | 3.01e-01 | 0.34 |
| 54989 | ZNF770 | ATC4 | Human | Thyroid | ATC | 3.64e-12 | 1.76e-01 | 0.34 |
| 54989 | ZNF770 | ATC5 | Human | Thyroid | ATC | 8.87e-16 | 2.44e-01 | 0.34 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ZNF770 | TRANS | Cervix | Healthy | LGALS7,PROK2,BCL2L2, etc. | 6.08e-02 |  |
| ZNF770 | ICAF | Esophagus | ESCC | SMOX,RP11-576I22.2,SLC8B1, etc. | 2.73e-01 |  |
| ZNF770 | INCAF | Esophagus | ESCC | SMOX,RP11-576I22.2,SLC8B1, etc. | 2.97e-01 | |
| ZNF770 | LC | Lung | Healthy | TIMP3,ELAVL1,TSEN2, etc. | 1.81e-03 |  |
| ZNF770 | MAST | Lung | MIAC | SOCS4,AC020656.1,FGD2, etc. | 2.11e-01 |  |
| ZNF770 | MSC.MVA | Oral cavity | ADJ | TUBA4A,SFN,SLPI, etc. | 7.20e-02 |  |
| ZNF770 | MSC.MVA | Oral cavity | Healthy | TUBA4A,SFN,SLPI, etc. | 6.13e-02 |  |
| ZNF770 | MSC.MVA | Oral cavity | LP | TUBA4A,SFN,SLPI, etc. | 6.73e-02 |  |
| ZNF770 | MSC.MVA | Oral cavity | NEOLP | TUBA4A,SFN,SLPI, etc. | 0.00e+00 |  |
| ZNF770 | FIB | Oral cavity | NEOLP | TUBA4A,SFN,SLPI, etc. | 0.00e+00 | |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 2 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ZNF770 | SNV | Missense_Mutation | novel | c.73A>T | p.Arg25Trp | p.R25W | Q6IQ21 | protein_coding | deleterious(0) | probably_damaging(0.962) | TCGA-A7-A6VW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR |
| ZNF770 | SNV | Missense_Mutation | novel | c.2023N>T | p.His675Tyr | p.H675Y | Q6IQ21 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AC-A3W7-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD |
| ZNF770 | SNV | Missense_Mutation | rs140429599 | c.1618G>C | p.Gly540Arg | p.G540R | Q6IQ21 | protein_coding | tolerated(0.1) | benign(0.125) | TCGA-AN-A0FW-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| ZNF770 | SNV | Missense_Mutation | novel | c.322C>G | p.Gln108Glu | p.Q108E | Q6IQ21 | protein_coding | tolerated(0.24) | benign(0.084) | TCGA-AQ-A7U7-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Targeted Molecular therapy | rituximab | CR |
| ZNF770 | SNV | Missense_Mutation | rs768441646 | c.1877N>A | p.Arg626Gln | p.R626Q | Q6IQ21 | protein_coding | tolerated(1) | benign(0) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| ZNF770 | SNV | Missense_Mutation | novel | c.470N>C | p.Lys157Thr | p.K157T | Q6IQ21 | protein_coding | deleterious(0.01) | possibly_damaging(0.835) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| ZNF770 | SNV | Missense_Mutation | novel | c.1610N>C | p.Val537Ala | p.V537A | Q6IQ21 | protein_coding | tolerated(0.12) | benign(0.003) | TCGA-ZJ-AAXA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| ZNF770 | SNV | Missense_Mutation | c.1981N>G | p.Thr661Ala | p.T661A | Q6IQ21 | protein_coding | deleterious(0.01) | benign(0.056) | TCGA-A6-6141-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | 5-fu | SD | |
| ZNF770 | SNV | Missense_Mutation | c.1528N>G | p.Lys510Glu | p.K510E | Q6IQ21 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AA-3710-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ZNF770 | SNV | Missense_Mutation | novel | c.1321N>C | p.Ser441Pro | p.S441P | Q6IQ21 | protein_coding | tolerated(0.15) | benign(0) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |